Becton Dickinson and Company (BDX)vsBioLife Solutions Inc (BLFS)
BDX
Becton Dickinson and Company
$190.74
-0.53%
HEALTHCARE · Cap: $52.23B
BLFS
BioLife Solutions Inc
$38.61
0.00%
HEALTHCARE · Cap: $1.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 20975% more annual revenue ($22.48B vs $106.69M). BLFS leads profitability with a 54.3% profit margin vs 4.2%. BDX appears more attractively valued with a PEG of 1.11. BDX earns a higher WallStSmart Score of 52/100 (C-).
BDX
Buy52
out of 100
Grade: C-
BLFS
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.8%
Fair Value
$202.39
Current Price
$190.74
$11.65 discount
Margin of Safety
-2.6%
Fair Value
$21.68
Current Price
$38.61
$16.93 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Keeps 54 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 21.5% year-over-year
Areas to Watch
ROE of 3.9% — below average capital efficiency
4.2% margin — thin
Premium valuation, high expectations priced in
Earnings declined 31.4%
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : BLFS
The strongest argument for BLFS centers on Profit Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 54.3% and operating margin at 6.0%. Revenue growth of 21.5% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are Return on Equity, Profit Margin, P/E Ratio. A P/E of 44.6x leaves little room for execution misses. Thin 4.2% margins leave little buffer for downturns.
Bear Case : BLFS
The primary concerns for BLFS are P/E Ratio, Market Cap, PEG Ratio.
Key Dynamics to Monitor
BDX profiles as a value stock while BLFS is a growth play — different risk/reward profiles.
BLFS carries more volatility with a beta of 1.82 — expect wider price swings.
BLFS is growing revenue faster at 21.5% — sustainability is the question.
BDX generates stronger free cash flow (509M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (52/100 vs 46/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?